Adalimumab (HUMIRA): a review.

@article{Scheinfeld2003AdalimumabA,
  title={Adalimumab (HUMIRA): a review.},
  author={Noah S. Scheinfeld},
  journal={Journal of drugs in dermatology : JDD},
  year={2003},
  volume={2 4},
  pages={
          375-7
        }
}
Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion. 

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…